60 related articles for article (PubMed ID: 35389069)
1. Efficacy and safety of
Clement D; Navalkissoor S; Srirajaskanthan R; Courbon F; Dierickx L; Eccles A; Lewington V; Mitjavila M; Percovich JC; Lequoy B; He B; Folitar I; Ramage J
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3529-3537. PubMed ID: 35389069
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.
Shin Y; Moon BH; Ryoo BY; Chang HM; Kim KP; Hong YS; Kim TW; Ryu JS; Kim YI; Yoo C
Target Oncol; 2024 Jan; 19(1):41-49. PubMed ID: 38108953
[TBL] [Abstract][Full Text] [Related]
3. The efficacy, toxicity and survival of salvage retreatment PRRT with
Sitani K; Parghane R; Talole S; Basu S
Br J Radiol; 2022 Sep; 95(1137):20210896. PubMed ID: 35816545
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Retreatment with
Delpassand ES; Yazdi SM; Ghantoji S; Nakasato A; Strickland C; Nunez R; Shafie A; Cork S; Byrne C; Tang J; Patel J
J Nucl Med; 2024 May; 65(5):746-752. PubMed ID: 38514088
[TBL] [Abstract][Full Text] [Related]
5.
Das S; Al-Toubah T; El-Haddad G; Strosberg J
Expert Rev Gastroenterol Hepatol; 2019 Nov; 13(11):1023-1031. PubMed ID: 31652074
[No Abstract] [Full Text] [Related]
6. Efficacy of [
Mitjavila M; Jimenez-Fonseca P; Belló P; Pubul V; Percovich JC; Garcia-Burillo A; Hernando J; Arbizu J; Rodeño E; Estorch M; Llana B; Castellón M; García-Cañamaque L; Gajate P; Riesco MC; Miguel MB; Balaguer-Muñoz D; Custodio A; Cano JM; Repetto A; Garcia-Alonso P; Muros MA; Vercher-Conejero JL; Carmona-Bayonas A
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2486-2500. PubMed ID: 36877234
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of 177 Lu-DOTATATE in Children and Young Adult Population : A Single-Center Experience.
Aggarwal P; Satapathy S; Sood A; Singh H; Mittal BR; Lal S; Gupta R; Das CK; Yadav TD; Walia R
Clin Nucl Med; 2024 Jul; 49(7):e312-e318. PubMed ID: 38769655
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II study of the safety and efficacy of [
Wild D; Grønbæk H; Navalkissoor S; Haug A; Nicolas GP; Pais B; Ansquer C; Beauregard JM; McEwan A; Lassmann M; Pennestri D; Volteau M; Lenzo NP; Hicks RJ
Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):183-195. PubMed ID: 37721581
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Everolimus Combined with
Aljubran A; Badran A; Alrowaily M; Raef H; Alzahrani AM; Almuhaideb A; Almanea H; El-Dali A; Tuli M; Bazarbashi S
Cancer Biother Radiopharm; 2024 Mar; 39(2):164-168. PubMed ID: 36342790
[No Abstract] [Full Text] [Related]
10. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
Love C; Desai NB; Abraham T; Banks KP; Bodei L; Boike T; Brown RKJ; Bushnell DL; DeBlanche LE; Dominello MM; Francis T; Grady EC; Hobbs RF; Hope TA; Kempf JS; Pryma DA; Rule W; Savir-Baruch B; Sethi I; Subramaniam RM; Xiao Y; Schechter NR
Am J Clin Oncol; 2022 Jun; 45(6):233-242. PubMed ID: 35507413
[TBL] [Abstract][Full Text] [Related]
11. p53 stabilisation potentiates [
Berglund H; Salomonsson SL; Mohajershojai T; Gago FJF; Lane DP; Nestor M
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):768-778. PubMed ID: 37823909
[TBL] [Abstract][Full Text] [Related]
12. Lutetium [
Lastoria S; Rodari M; Sansovini M; Baldari S; D'Agostini A; Cervino AR; Filice A; Salgarello M; Perotti G; Nieri A; Campana D; Pellerito RE; Pomposelli E; Gaudieri V; Storto G; Grana CM; Signore A; Boni G; Dondi F; Simontacchi G; Seregni E
Eur J Nucl Med Mol Imaging; 2024 May; ():. PubMed ID: 38772998
[TBL] [Abstract][Full Text] [Related]
13. Initial Findings on the Use of [
Demirci E; Alan Selçuk N; Beydağı G; Ocak M; Toklu T; Akçay K; Kabasakal L
Mol Imaging Radionucl Ther; 2023 Oct; 32(3):226-232. PubMed ID: 37870290
[TBL] [Abstract][Full Text] [Related]
14. Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with
Strosberg JR; Srirajaskanthan R; El-Haddad G; Wolin EM; Chasen BR; Kulke MH; Bushnell DL; Caplin ME; Baum RP; Hendifar AE; Öberg K; Ruszniewski P; Santoro P; Broberg P; Leeuwenkamp OR; Krenning EP
J Nucl Med; 2021 Mar; 62(12):1712-8. PubMed ID: 33771903
[TBL] [Abstract][Full Text] [Related]
15. Dosing lutetium Lu 177-dotatate for a hemodialysis patient.
Taylor L; Meades R; Quigley AM; Toumpanakis C; Goodlad C; Davenport A
Hemodial Int; 2024 Apr; 28(2):247-252. PubMed ID: 38448766
[TBL] [Abstract][Full Text] [Related]
16. Maximum tumor diameter and renal function can predict the declining surface dose rate after
Ono T; Ichikawa M; Tanada T; Kanezawa C; Sato H
Jpn J Radiol; 2024 May; ():. PubMed ID: 38727960
[TBL] [Abstract][Full Text] [Related]
17. Successful Combination of Olaparib and
Kröcher A; Folprecht G; Winzer R; Sergon M; Bornhäuser M; Kotzerke J; Brogsitter C
Case Rep Oncol; 2023; 16(1):1166-1171. PubMed ID: 37900794
[TBL] [Abstract][Full Text] [Related]
18. Remarkable regression of inoperable pancreatic grade 3 neuroendocrine neoplasm after radioligand therapy with [177Lu]Lu-DOTATATE and [90Y]Y‑DOTATATE.
Durma AD; Saracyn M; Kołodziej M; Jóźwik-Plebanek K; Kamiński G
Pol Arch Intern Med; 2023 Nov; 133(11):. PubMed ID: 37795839
[No Abstract] [Full Text] [Related]
19. New Developments in the Treatment of Neuroendocrine Tumours - RADIANT-4, NETTER-1 and Telotristat Etiprate.
Sbardella E; Grossman A
Eur Endocrinol; 2016 Mar; 12(1):44-46. PubMed ID: 29632589
[TBL] [Abstract][Full Text] [Related]
20. Transcatheter arterial embolization in patients with neuroendocrine neoplasms related to liver metastasis with different blood supplies.
Bai J; Song J; Zhang Y; Li X; Yan L; Hu P; Tang Q
Cancer Med; 2023 Sep; 12(18):18578-18587. PubMed ID: 37587855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
